Rizzetto Giulio, Gambini Daisy, Maurizi Andrea, Molinelli Elisa, De Simoni Edoardo, Pallotta Francesco, Brescini Lucia, Cirioni Oscar, Offidani Annamaria, Simonetti Oriana, Giacometti Andrea
Clinic of Dermatology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.
Clinic of Infectious Diseases, Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy.
Infez Med. 2023 Sep 1;31(3):306-322. doi: 10.53854/liim-3103-5. eCollection 2023.
Antibiotic resistance of Gram-positive and Gramnegative bacteria is becoming increasingly prevalent. For this reason, the search for new molecules that can overcome current resistance and also recover antibiotics that are no longer effective is becoming increasingly urgent. Our research group at the 'Polytechnic University of Marche' managed to study the effectiveness of certain antimicrobial peptides (AMPs). We decided to review our experience with AMPs by classifying them according to their origin and evaluating their effect on Gram-negative and Gram-positive bacteria. AMPs can derive from mammals, amphibians, microorganisms, and insects. In conclusion, our research experience shows that the richest source of AMPs are amphibians. However, the studies done are mainly in vitro or in animal models, requiring further human studies to assess the efficacy and safety of these molecules. AMPs may be a new therapeutic option for infections sustained by multi-resistant micro-organisms and for overcoming the mechanisms of resistance to antibiotics currently used. In particular, combining AMPs with antibiotics, including those with limited antimicrobial activity due to antimicrobial resistance, has often shown a synergistic effect, increasing or restoring their efficacy. The possibility of using manageable and relatively safe antibiotics again is crucial, considering the widespread increase in bacterial resistance in hospitals and the community. Despite a plethora of research on AMPs and their application as potential treatment on infectious diseases, this area needs further exploration. There is evidence that the characteristics of AMPs can seriously improve through structural chemical modifications and different delivery systems to become alternatives drugs to conventional antibiotics. The aim is to provide an overview of the possible sources from which AMPs are extracted, evaluating their action exclusively on Gram-positive and negative bacteria. This is to determine, based on our experience, which might be the most promising sources of AMPs for future research as well.
革兰氏阳性菌和革兰氏阴性菌的抗生素耐药性正变得越来越普遍。因此,寻找能够克服当前耐药性并恢复不再有效的抗生素的新分子变得越来越紧迫。我们马尔凯理工大学的研究小组成功研究了某些抗菌肽(AMPs)的有效性。我们决定通过根据抗菌肽的来源对其进行分类并评估它们对革兰氏阴性菌和革兰氏阳性菌的作用来回顾我们对抗菌肽的经验。抗菌肽可以来源于哺乳动物、两栖动物、微生物和昆虫。总之,我们的研究经验表明,抗菌肽最丰富的来源是两栖动物。然而,所做的研究主要是在体外或动物模型中进行的,需要进一步的人体研究来评估这些分子的疗效和安全性。抗菌肽可能是治疗多重耐药微生物感染和克服目前使用的抗生素耐药机制的一种新的治疗选择。特别是,将抗菌肽与抗生素联合使用,包括那些由于抗菌耐药性而抗菌活性有限的抗生素,常常显示出协同效应,增强或恢复它们的疗效。考虑到医院和社区中细菌耐药性的广泛增加,再次使用易于管理且相对安全的抗生素的可能性至关重要。尽管对抗菌肽及其作为传染病潜在治疗方法的应用进行了大量研究,但这一领域仍需进一步探索。有证据表明,通过结构化学修饰和不同的递送系统,抗菌肽的特性可以得到显著改善,从而成为传统抗生素的替代药物。目的是概述提取抗菌肽的可能来源,仅评估它们对革兰氏阳性菌和阴性菌的作用。这也是根据我们的经验来确定哪些可能是未来研究中最有前景的抗菌肽来源。